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Objective: To determine the secretion of A-type and B-type natriuretic peptides into
the bloodstream and pericardial space in children with congenital heart disease.
Methods: Plasma and pericardial fluid samples were obtained from 77 patients
undergoing total correction for congenital heart disease. All patients underwent
detailed right-sided and left-sided cardiac catheterization preoperatively.
Results: A-type natriuretic peptide levels in pericardial fluid were lower than those
in plasma (33.0  23.1 versus 39.8  33.6 pg/mL, P  .05), and B-type natriuretic
peptide levels in pericardial fluid showed marked elevations compared with those in
plasma (231.9  305.6 versus 19.8  29.3 pg/mL, P  .0001). The A-type and
B-type natriuretic peptide levels in plasma correlated with those in pericardial fluid
(R  .522, P  .0001; R  .595, P  .0001). For A-type and B-type natriuretic
peptide levels in plasma, the relation with biventricular volume had the highest
correlation (R  .669, P  .0001; R  .652, P  .0001). The patients with a
pulmonary-to-systemic flow ratio greater than 2 (n  19) had high levels of
natriuretic peptides not only in plasma (58.3  43.2, 40.5  49.4 pg/mL, P  .05)
but also in pericardial fluid (44.4  31.5, 287.2  198.5 pg/mL, P  .05), and
higher correlation between A-type and B-type natriuretic peptide plasma levels and
left ventricular volume (R  .913, P  .0001; R  .787, P  .0001).
Conclusions: B-type natriuretic peptide is secreted not only into the bloodstream but
also into the pericardial space in children with congenital heart disease. Natriuretic
peptide levels in plasma correlated well with biventricular volume. The left ventricle
was considered to be the main source of secreted natriuretic peptides in the patients
with a pulmonary-to-systemic flow ratio greater than 2.
A-type (atrial) and B-type (brain) natriuretic peptides (ANP andBNP) are circulating peptides produced principally by the atriaand ventricles, respectively.1,2 Both peptides increase sodium andwater excretion, suppress renin and aldosterone secretion, andlead to venous and arterial dilatation.3 They may also favorablyinfluence autonomic function and have direct and indirect anti-
mitotic effects in the heart and blood vessels.4 It was believed that most of the ANP
and BNP was secreted into the bloodstream and acted as a systemic hormone. ANP
and BNP have also been reported to have local autocrine and paracrine functions at
the site of their synthesis5,6 and to be secreted into the pericardial space.7 Now, ANP
and BNP play an important part in the diagnosis of chronic heart failure (CHF),8
predict late-term survival,9 and are used to treat CHF.10,11 Although many reports
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have examined plasma ANP and BNP concentrations in
adults with CHF, few have explored the natriuretic peptide
concentrations in children with congenital heart disease
(CHD).12-14 Furthermore, the secretion of ANP and BNP as
a component of the pericardial fluid (PF) into the pericardial
space in CHD is still unknown. The purposes of this study
were to determine (1) whether ANP and BNP are secreted
into the pericardial space in children with CHD, (2) whether
the levels of ANP and BNP correlate with the severity of the
disease, and (3) whether the levels of ANP and BNP differ
in some diseases.
Patients and Methods
The study was approved by the local institutional review board and
all parents gave written informed consent. The study was com-
prised of 77 children, aged 3 months to 14 years, undergoing
elective preoperative cardiac catheterization before the surgery for
definitive repair of the congenital cardiac malformation. Informed
consent was obtained from each participating patient. The main
cardiac diagnoses are listed in Table 1. The children were divided
into 3 groups: group 1, those with a pulmonary-to-systemic flow
ratio less than 1; group 2, those with a pulmonary-to-systemic flow
ratio 1 to 2; group 3, those with a pulmonary-to-systemic flow ratio
greater than 2. Thirty-two of 77 patients had total of 40 previous
operations or catheter interventions. The type and number of
operations or interventions were 14 pulmonary artery bandings, 18
Blalock-Taussig shunts, 2 aortopulmonary shunts, 1 repair of total
pulmonary venous drainage, and 5 balloon pulmonary valvuloplas-
ties.
All patients underwent right-sided and left-sided cardiac cath-
eterizations. Left atrial pressure was obtained by direct measure-
ment or by measuring the average of the bilateral pulmonary
capillary wedge pressure. Right and left ventricular volumes were
calculated from biplane cineangiograms. Right ventricular vol-
umes were calculated using Simpson’s rule method, and left ven-
tricular volumes were calculated by the area-length method. Right
ventricular end-diastolic volume (RVEDV) and left ventricular
end-diastolic volume (LVEDV) were corrected for body surface
area (BSA) and were expressed RVEDV index (RVEDVI) and
LVEDV index (LVEDVI). RVEDV and LVEDV were also ex-
pressed as a percentage of the predicted normal values using the
formula derived by Nakazawa and colleagues.15
Predicted normal RVEDV (mL)  75.1  BSA m21.43
Predicted normal LVEDV (mL)  72.5  BSA m21.43
RV%Normal (%) and LV%Normal (%) were expressed as a per-
centage of the predicted normal RVEDV and LVEDV. TV(total
volume)%Normal (%) was calculated by adding RV%Normal and
LV%Normal.
The definitive repair for congenital heart defects was performed
in all patients within 3 months after the cardiac catheterization. All
patients with a single ventricle underwent total cavopulmonary
connection. Plasma ANP and BNP concentrations were withdrawn
from the cannulated brachial artery after induction of anesthesia
and before skin incision. Undiluted samples of pericardial fluid
were obtained immediately after the incision of the pericardium.
Each blood specimen was collected in a chilled tube containing 4.5
TABLE 1. Main diagnosis in 77 patients
Main diagnosis Number
Ventricular septal defect 16
 Pulmonary hypertension 6
 Pulmonary artery banding 8
Atrial septal defect 14
Tetralogy of Fallot 12
Single ventricle 6
Pulmonary atresia 5
Double-outlet right ventricle 4
Atrioventricular septal defect with pulmonary artery
banding
4
Transpositions of great arteries 1
Double-chambered right ventricle 1







Age (y) 5.3 2.4 6.2 3.0 6.3 3.9
Weight (kg) 16.5 8.6 21.3 13.0 20.9 11.6
MRAP (mm Hg) 3.8 1.3 3.9 2.1 3.7 2.2
SRVP (mm Hg) 96.9 13.4 64.3 30.3† 52.6 23.1†
MLAP (mm Hg) 6.0 3.5 7.0 2.6 6.8 3.9
LVEDP (mm Hg) 8.2 1.2 9.8 3.6 8.7 4.2
Qp/Qs 0.74 0.28 1.37 0.29* 2.86 1.58*†
RVESVI (mL/m2) 23.9 11.8 30.2 9.6 35.6 8.1*
RVEDVI (mL/m2) 69.3 26.5 76.7 24.3 91.0 20.8*
RVEF (%) 64.6 9.4 60.1 8.5 64.5 19.2
LVESVI (mL/m2) 22.0 5.7 26.0 11.4 25.9 17.3
LVEDVI (mL/m2) 65.8 16.5 81.4 29.8 78.4 37.2
LVEF (%) 66.4 7.1 67.9 7.8 67.8 9.2
RV%Normal (%) 116.5 39.6 121.6 36.7 148.2 36.2*†
LV%Normal (%) 116.1 27.7 135.9 57.0 139.1 85.5
TV%Normal (%) 226.2 26.1 248.0 62.0 280.0 99.0
ANP in plasma (pg/
mL)
29.5 23.5 35.7 29.5 58.3 43.2*†
BNP in plasma (pg/
mL)
10.4 9.7 14.2 15.0 40.5 49.4*†
ANP in PF (pg/mL) 30.1 13.5 27.9 18.7 44.4 31.5†
BNP in PF (pg/mL) 121.1 21.0 159.6 25.7 287.2 198.5*†
The children were divided into 3 groups: group 1, those with a pulmonary-
to-systemic flow ratio less than 1; group 2, those with a pulmonary-to-
systemic flow ratio 1 to 2; group 3; those with a pulmonary-to-systemic
flow ratio greater than 2.
MRAP, Mean atrial pressure; SRVP, systolic right ventricular pressure;
MLAP, mean left atrial pressure; LVEDP, left ventricular end-diastolic
pressure; Qp/Qs, pulmonary flow to systemic flow ratio; RVESVI, right
ventricular end-systolic volume index; RVEDVI, right ventricular end-dia-
stolic volume index; RVEF, right ventricular ejection fraction; LVESVI, left
ventricular end-systolic volume index; LVEDVI, left ventricular end-dia-
stolic volume index; LVEF, left ventricular ejection fraction; ANP, A-type
natriuretic peptide; BNP, B-type natriuretic peptide; PF, pericardial fluid.
Data are expressed as mean value  SD.
*P  .05 vs. group 1.
†P  .05 vs. Group 2.
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mg of sodium ethylenediaminetetraacetic acid and 1500 units of
aprotinin. The pericardial fluid was collected in sterile tubes. Each
sample was placed immediately on ice, separated by centrifugation
at 3000g for 10 minutes at 4°C and rapidly frozen at 80°C until
a hormone assay was performed. Concentrations of ANP and BNP
in the plasma and pericardial fluid were measured by a commer-
cially available specific radioimmunoassay system (SRL Inc, To-
kyo, Japan). The concentrations of ANP and BNP were expressed
in picograms per milliliter, and their normal ranges were less than
40 pg/mL and 20 pg/mL, respectively.
All values were expressed as mean  standard deviation. An
unpaired Student t test and 1-way repeated-measures analysis of
variance were used to assess the differences in hemodynamic and
hormonal data. When the differences were determined by the
1-way repeated-measures analysis of variance to be significant, the
differences were further analyzed by the Scheffe´ test. Differences
were considered significant at P  .05. The correlations between
differences in natriuretic peptide levels of plasma and hemodynamic,
hormonal variables were calculated by linear regression analysis.
Results
ANP levels in PF were less than those in plasma (33.0 
23.1 versus 39.8  33.6 pg/mL, P  .05), and BNP levels
in PF showed marked elevations compared with those in
plasma (231.9  305.6 versus 19.8  29.3 pg/mL, P 
.0001). Figure 1, A and B show the relationships between
natriuretic peptide levels in plasma and those in PF. The
ANP and BNP levels in plasma correlated with those in PF
(R  .522, P  .0001; R  .595, P  .0001, respectively).
Hemodynamic and hormonal data in each group are
listed in Table 2. The patients in group 3 had the highest
levels of ANP and BNP levels not only in the plasma (58.3
 43.2, 40.5 49.4 pg/mL) but also in the PF (44.4 31.5,
287.2  198.5 pg/mL).
The correlation coefficients for the relation between each
of the independent variables and natriuretic peptide levels
from 2 sampling sites in all patients are listed in Table 3,
and those in each group are listed in Tables 4, 5, and 6. For
ANP and BNP plasma levels in all patients, the relation with
TV%Normal had the highest correlation (Figure 2, A and B)
(R  .669, P  .0001; R  .652, P  .0001, respectively).
For ANP and BNP plasma levels, the relation with
RV%Normal had a tendency of higher correlation in group
1 (R  .655, P  .0032; R  .523, P  .0260, respectively)
and group 2 (R  .642, P  .0001; R  .613, P  .0001,
respectively) compared with LV%Normal, while the rela-
tion with LV%Normal had higher correlation in group 3 (R
 .913, P  .0001; R  .787, P  .0001, respectively)
compared with RV%Normal.
Discussion
ANP and BNP are released mainly from atrial and ventric-
ular myocytes, respectively. Most of the ANP and BNP
were believed to be secreted into the bloodstream and act as
a systemic hormone. However, a recent study reported that
natriuretic peptides are secreted from the heart into the
pericardial space in response to left ventricular dysfunc-
tion,7 and they might have a pathophysiologic role in heart
failure as an autocrine and paracrine factor.5,6 Klemola and
colleagues16 also reported that a previous anterior myocardial
infarction was associated with increased cardiac BNP produc-
tion even if the left ventricular systolic function was normal.
The present study demonstrated that BNP levels in PF
showed marked elevations compared with those in plasma,
and ANP levels in PF were lower than those in plasma. The
BNP level in PF was 5.9-fold higher when compared with
the BNP level in plasma. Tanaka and associates7 reported
that the ANP level in PF was 8.9-fold and BNP level 27-fold
higher when compared with the ANP and BNP levels in
plasma. Klemola and associates16 also reported that the
ANP level in PF was 2.5-fold and BNP level 4.2-fold higher
when compared with the ANP and BNP levels in plasma.
Our results of BNP in PF are similar to these results.
However, BNP levels in plasma and PF of our patient did
not reach as a high level as Tanaka and colleagues report-
ed.7 That may be because that the patients in Tanaka and
Figure 1. A and B, The relations between natriuretic peptide levels in plasma and those in PF.
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colleagues’ study included many heart failure patients who
had high BNP/ANP ratio in plasma. Conversely, the plasma
BNP/ANP ratio is reversed in CHF in our study. Bolger and
associates17 also reported that the plasma concentration of
BNP was lower than that of ANP in adults with CHD. These
results may suggest that the degree of heart failure was mild
in our patients with CHD or that there were some differ-
ences in the mechanism of BNP secretion between CHD in
TABLE 3. Linear regression analyses of association between hemodynamic variables and ANP and BNP levels in plasma
and PF (all patients: n  77)
ANP in plasma BNP in plasma ANP in PF BNP in PF
Coefficient P value Coefficient P value Coefficient P value Coefficient P value
Qp/Qs .4860 .0001 .3800 .5354 .1420 .2646 .3080 .0133
RVESVI .1580 .1810 .2200 .6190 .2500 .0430 .3420 .0049
RVEDVI .0082 .4920 .1240 .2962 .2280 .0659 .3270 .0074
RVEF .1140 .3309 .0830 .4800 .0280 .8215 .1430 .2535
LVESVI .4860 .0001 .5750 .0001 .2320 .0630 .1430 .2535
LVEDVI .4760 .0001 .5020 .0001 .1700 .1762 .1370 .2762
LVEF .1300 .2708 .1810 .1219 .1510 .2296 .0940 .4566
RV%Normal .3710 .0011 .3200 .0055 .4090 .0007 .4600 .0001
LV%Normal .6250 .0001 .5750 .0001 .2680 .0308 .2030 .1044
TV%Normal .6690 .0001 .6520 .0001 .3340 .0054 .4190 .0004
See Table 2 for abbreviations.
TABLE 4. Linear regression analyses of association between hemodynamic variables and ANP and BNP levels in plasma
and PF (group 1: n  18)
ANP in plasma BNP in plasma ANP in PF BNP in PF
Coefficient P value Coefficient P value Coefficient P value Coefficient P value
Qp/Qs .6130 .0089 .6910 .0021 .0200 .9493 .1720 .5744
RVESVI .5240 .0257 .4000 .1003 .5750 .0314 .3220 .2609
RVEDVI .7470 .0004 .5760 .0124 .6460 .0125 .0630 .8295
RVEF .3780 .1219 .2940 .2364 .0260 .9303 .5630 .0361
LVESVI .0840 .7496 .3220 .2075 .3450 .2476 .3260 .2763
LVEDVI .0800 .7608 .3580 .1587 .6520 .0158 .2240 .4610
LVEF .1120 .6682 .0870 .7393 .1560 .6103 .2310 .4471
RV%Normal .6550 .0032 .5230 .0260 .4610 .0970 .1490 .6109
LV%Normal .4440 .0740 .6330 .0064 .1140 .7102 .3910 .1864
TV%Normal .3290 .1827 .2290 .3605 .3780 .1823 .3300 .2497
See Table 2 for abbreviations.
TABLE 5. Linear regression analyses of association between hemodynamic variables and ANP and BNP levels in plasma
and PF (group 2: n  40)
ANP in plasma BNP in plasma ANP in PF BNP in PF
Coefficient P value Coefficient P value Coefficient P value Coefficient P value
Qp/Qs .0230 .8923 .0520 .7616 .0020 .9918 .0920 .6165
RVESVI .3600 .0285 .4010 .0139 .5900 .0003 .7160 .0001
RVEDVI .3700 .0240 .4200 .0096 .4730 .0054 .5980 .0002
RVEF .0670 .6887 .0800 .6323 .1850 .3017 .1710 .3407
LVESVI .2120 .2022 .1350 .4177 .3870 .0237 .1870 .2903
LVEDVI .2710 .0999 .2730 .0976 .4850 .0036 .3200 .0649
LVEF .0350 .8322 .1490 .3668 .0940 .5957 .1630 .3573
RV%Normal .6420 .0001 .6130 .0001 .6530 .0001 .7250 .0001
LV%Normal .4050 .0105 .3290 .0410 .5670 .0005 .3520 .0409
TV%Normal .5870 .0001 .5720 .0001 .4810 .0034 .5850 .0002
See Table 2 for abbreviations.
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children and ischemic heart disease in adults. Ischemia or
infarction of cardiomyocytes may play an important role in
elevating BNP levels in PF.7
On the other hand, our results of ANP in PF did not
indicate high levels when compared with the BNP in PF.
Yasue and associates2 reported that the ANP levels in a
coronary sinus showed marked elevation (15.5-fold) com-
pared with levels in the aortic root, whereas the BNP levels
in the coronary sinus only showed more than 4 times the
levels in the aortic root. The differences of natriuretic pep-
tide level in PF suggest that BNP is secreted predominantly
into the pericardial space rather than into the bloodstream or
that BNP has a longer half-life in the pericardial fluid than
in plasma. Maack and associates18 reported that the circu-
lating ANP and BNP were cleared by their clearance recep-
tor. Suga and associates19 reported that the affinity of the
clearance receptor (C-receptor) of ANP, which is expressed
in a wide variety of tissues, was higher than that of BNP.
This effect may be responsible partially for the marked
elevation of the BNP in PF.
In adult patients, left ventricular end-systolic volume
index (LVESVI) or left end-diastolic volume index
(LVEDVI) has a significant relationship with ANP or BNP
levels in plasma.2 However, our results demonstrated the
highest relationships between natriuretic peptides and
TV%Normal. It is important to note that LVEDV/BSA or
RVEDV/BSA should not be used for normalization of end-
diastolic volumes for patient size because the relationships
between EDV and BSA were neither linear nor proportional
in normal children, thus the ratio of EDV/BSA will change
with BSA and show erroneous differences when comparing
groups of different mean age. Furthermore, many hearts
with CHD have a diseased right ventricle. It is essential to
estimate not only the diseased left ventricle but also the
diseased right ventricle in considering the secretion of na-
triuretic peptides.
As we did not measure the ANP levels in the coronary
sinus or anterior interventricular vein, it was unknown
whether increased amounts of ANP were secreted from the
atrium or the ventricle. Both ANP and BNP in plasma
TABLE 6. Linear regression analyses of association between hemodynamic variables and ANP and BNP levels in plasma
and PF (group 3: n  19)
ANP in plasma BNP in plasma ANP in PF BNP in PF
Coefficient P value Coefficient P value Coefficient P value Coefficient P value
Qp/Qs .4230 .0710 .1410 .5649 .1370 .5750 .0060 .9818
RVESVI .2130 .3815 .0360 .8841 .2220 .3606 .1960 .4219
RVEDVI .3780 .1107 .2780 .2500 .1700 .4866 .1460 .5505
RVEF .2370 .3277 .1860 .4453 .0170 .9449 .1560 .5230
LVESVI .8530 .0001 .9010 .0001 .1940 .4401 .2150 .3927
LVEDVI .8570 .0001 .7980 .0001 .0190 .9415 .0600 .8120
LVEF .4040 .0960 .5020 .0338 .4430 .0655 .3430 .1635
RV%Normal .1320 .5902 .0850 .7291 .3780 .1104 .3630 .1262
LV%Normal .9130 .0001 .7870 .0001 .0610 .8105 .1390 .5825
TV%Normal .8420 .0001 .7340 .0003 .1900 .4354 .2920 .2259
See Table 2 for abbreviations.
Figure 2. A and B, The relations between natriuretic peptide levels in plasma and TV%Normal.
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exhibited high correlation with TV%Normal, not with the
atrial pressure of the right and left atrium. These results
suggest that ANP may be secreted to the bloodstream not
only from the atrium but also the ventricle in these dilated
ventricles with CHD.
The present study demonstrated that the secretions of
natriuretic peptides were different in each group of congen-
ital heart disease. The patients with a pulmonary-to-sys-
temic flow ratio greater than 2 had higher ANP and BNP
levels in plasma and higher correlation between ANP and
BNP plasma levels and left ventricular volume, while the
patients with a pulmonary-to-flow ratio less than 2 had
lower ANP and BNP levels in plasma and higher correlation
between ANP and BNP plasma levels and right ventricular
volume. The present study did not demonstrate whether the
natriuretic hormone was highly secreted from a left ventri-
cle or a right ventricle. However, the high correlation be-
tween natriuretic hormone and the left ventricle suggests
that the left ventricle was the main source of secreted
natriuretic peptides.
An obvious limitation of our study is the number of
patients. Activation of neurohormonal systems in children
with CHD has been described, but the broader relevance of
these individual findings to CHD populations as a whole has
been difficult to gauge because common clinical denomina-
tors have been difficult to apply to this anatomically heter-
ogeneous population. Further studies in a larger number of
patients (particularly those with cyanotic heart disease and
ventricular septal defect with pulmonary hypertension) are
needed to clarify the contribution of each factor to the levels
of ANP and BNP in plasma and PF. The second limitation
of this study is a lack of normal children as a control. The
normal range of natriuretic peptides in children had already
been reported by Yoshibayashi and associates in 1995.20
They reported that the ANP and BNP levels in healthy
children were the highest at 0 days of age and decreased
through maturation to be almost constant at the adult level
at 3 months of age. In this study group, the normal range of
the ANP and BNP levels was considered to be the same as
the adult level, expressed in femtomole per milliliter. Al-
though the assay and units of natriuretic peptide levels are
different between Yoshibayashi and colleagues’ study and
our study, the value of natriuretic peptides expressed in
femtomole per milliliter can be calculated, as the molecular
weights of ANP and BNP are known to be 3080.5 and
3464.1. Therefore, the normal range of specific radioimmu-
noassay system in adults as less than 40 pg/mL and 20
pg/mL, respectively, will be applicable to the normal range
in children. However, the normal range of the ANP and
BNP levels in PF in normal children is still unclear.
In summary, BNP is secreted not only into the blood-
stream but also into the pericardial space in children with
CHD. Natriuretic peptides levels in plasma correlated well
with biventricular volume. The patients with a pulmonary-
to-systemic flow ratio greater than 2 had higher correlation
between ANP and BNP plasma levels and left ventricular
volume. These results suggest that the left ventricle was the
main source of secreted natriuretic peptides.
We thank Mr. Michael Kopcak for editorial advice.
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